News Related to Treprostinil Palmitil

Related coverage linked through entity extraction aliases.

Pharmaceutical Market Forecasts: Respiratory, Fibrosis, and Digital Health Segments Project Growth

Jun 06, 2026

Recent market reports forecast significant growth in the progressive pulmonary fibrosis market, set to reach $2.7 billion by 2035, and the global asthma and COPD drugs market, projected to hit US$ 82.2 billion by 2036. The Asia Pacific pharma 4.0 market is also expanding rapidly, driven by digital technologies like AI and IoT.

Insmed Reports Strong 2025 Results, FDA Grants Orphan Drug Status to Treprostinil Palmitil

Feb 28, 2026

Insmed reported total revenues of $606.4 million for 2025, with ARIKAYCE growing 19% annually. The FDA granted orphan drug designation to treprostinil palmitil for pulmonary arterial hypertension treatment in January 2026.